

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED**

**阿里健康信息技術有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 00241)**

### **RE-DESIGNATION OF DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**”) of Alibaba Health Information Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that, Mr. Zhu Shunyun (“**Mr. Zhu**”), executive Director of the Company, will be re-designated (the “**Re-designation**”) from an executive Director to a non-executive Director with effect from September 1, 2024, as he would like to devote more time on the overall strategic planning of the Group and industry development. After the Re-designation, Mr. Zhu will remain as the Chairman of the Board and the chairman of the nomination committee (the “**Nomination Committee**”) of the Company.

The biography of Mr. Zhu is set out below:

Mr. ZHU Shunyan, aged 53, was appointed as an executive Director and the chairman of the Board on March 16, 2020. He is currently the chairman of the Nomination Committee. From March 16, 2020 to November 28, 2023, he served as the chief executive officer of the Company. Mr. Zhu is a partner of the Alibaba Partnership and was the President of the Innovation Initiatives Segment of the ultimate controlling shareholder of the Company, Alibaba Group Holding Limited (“**Alibaba Holding**” with its American depositary shares, each representing eight ordinary shares, listed on the New York Stock Exchange (stock symbol: BABA), and its ordinary shares listed on the Main Board of the Stock Exchange (stock code: 9988), together with its subsidiaries, “**Alibaba Group**”). He was a director of Meinian Onehealth Healthcare Holdings Co., Ltd.^ (美年大健康產業控股股份有限公司), a company listed on the Shenzhen Stock Exchange (stock code: 2044) from May 2020 to October 2021. Prior to joining Alibaba Group, Mr. Zhu founded Wuhan Xuncaï Technology Co., Ltd.^ (武漢迅彩科技公司) in 2003. He joined the founding team of UC Browser in 2007 as senior vice president, and was responsible for the marketing and commercialization of UC Browser. The business of UC Browser was acquired by Alibaba Group in June 2014. Subsequently, Mr. Zhu had served as (i) the

president of Alimama Business Group, a leading big data marketing platform in the PRC operated by Alibaba Group; (ii) the president of UC Browser; (iii) the president of New Media Businesses of Alibaba Digital Media & Entertainment Business Group, responsible for the business departments of UC Browser, Alibaba Music and Innovation Business; and (iv) the president of the Intelligent Information Business Group. Mr. Zhu obtained a Bachelor of Science Degree in Mathematics in 1993 from Yanshan University in the PRC. He obtained a Master Degree in Computing Software in 1996 from Huazhong University of Science and Technology in the PRC.

As at the date of this announcement, Mr. Zhu beneficially held 1,464,489 ordinary shares of the Company and subject to vesting, he is interested in 9,319,424 shares underlying the 7,734,125 options and 1,585,299 restricted share units granted to him in accordance with the Company's share award scheme.

Save as disclosed herein and as at the date of this announcement, Mr. Zhu (i) is not interested or deemed to be interested in any shares or underlying shares of the Company pursuant to Part XV of the Securities and Future Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) does not have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders of the Company; and (iii) does not hold any directorship in any other Hong Kong or overseas listed public companies in the last three years preceding the date of this announcement, or any other position with the Company or other members of the Group.

In respect of the Re-designation, Mr. Zhu will enter into an appointment letter with the Company for a term of three years in relation to his appointment as a non-executive Director the Company, commencing from September 1, 2024, which is renewable for a three-year period upon expiry of such term. He is subject to retirement by rotation and re-election at the annual general meetings of the Company in accordance with the bye-laws of the Company and the Listing Rules. As proposed by the Remuneration Committee of the Company, Mr. Zhu's monthly salary shall be RMB81,000, which was determined with reference to Mr. Zhu's duties and responsibilities and the prevailing market conditions, and as approved by the Board of Directors.

Save as disclosed herein, Mr. Zhu has confirmed that he had no disagreement with the Board, and there is no other information required to be disclosed in accordance with Rule 13.51(2)(h) to (v) of the Listing Rules and there is no other matter relating to the Re-designation that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange.

The Board would like to take this opportunity to express its appreciation for the valuable contributions made by Mr. Zhu to the Company during his tenure of service as the executive Director of the Company.

For and on behalf of the Board  
**Alibaba Health Information Technology Limited**  
**Shen Difan**  
*Chief Executive Officer*

<sup>^</sup> *For identification purposes only*

Hong Kong, August 30, 2024

*As at the date of this announcement, the Board comprises Mr. Zhu Shunyan, Mr. Shen Difan and Mr. Tu Yanwu as the executive Directors; Ms. Huang Jiaojiao and Mr. Xu Haipeng as the non-executive Directors; and Ms. Huang Yi Fei (Vanessa), Dr. Shao Rong and Ms. Wu May Yihong as the independent non-executive Directors.*